VIVO BIO TECH
VIVOBIOTVerifiedVIVO BIO TECH is a publicly traded security listed on the NSE/BSE exchange.
Stock Snapshot & Key Numbers — VIVO BIO TECH
Verified Daily CloseOfficial closing price, 1-year price range, valuation multiples, and market value from exchange records.
VIVO BIO TECH (VIVOBIOT) is a Indian equity security listed on the NSE/BSE with ISIN BSE:511509. As of the last recorded market session on Close on 16 Oct 2026, the stock closed at ₹14.37, recording a +0.44 (+3.16%) advance from its previous close of ₹13.93. Over the trailing 52-week trading cycle, VIVOBIOT has traded between a 52-week low of ₹13.87 and a 52-week high of ₹19.29, establishing its annual trading channel. In historical performance, VIVO BIO TECH has fallen 24.76% over the past 1 year. Period returns across standard measurement intervals include: 1-week: -3.75%, 1-month: -14.62%, 6-month: -24.76%, 1-year: -24.76%, 3-year: -24.76%, 5-year: -24.76%. Daily reported trading volume reached 50,166 equity shares. On key valuation multiples as of 11 Oct 2026, the company trades at a trailing price-to-earnings (P/E) multiple of not meaningful (negative earnings) and a price-to-book (P/B) ratio of 0.3x, with a trailing dividend yield of 0.00%. Its market capitalization stands at ₹33.13 Cr. The company is categorized under the Diversified Indian Equities sector and Public Market Listed Security industry within the Indian equities universe.
Price Chart
Trading Multiples & Ranges
Price boundaries and liquidity distribution.
How Outside Factors Affect This Stock (Market, Crude Oil & Currency)
How closely this stock moved with the broader market index, crude oil, and the exchange rate over the past year.
| Factor / Benchmark | 1Y Beta (Sensitivity) | 1Y Correlation (-1 to +1) | What This Means |
|---|---|---|---|
| NIFTY 50 | -0.91 | -0.18 | Trailing 1Y historical sensitivity: a 1% move in NIFTY 50 coincided with a -0.91% co-movement (correlation: -0.18). Descriptive historical relationship, not predictive. |
| USD / INR | -0.43 | -0.06 | Trailing 1Y historical sensitivity: a 1% move in USD / INR coincided with a -0.43% co-movement (correlation: -0.06). Descriptive historical relationship, not predictive. |
| Brent Crude Oil | -0.26 | -0.15 | Trailing 1Y historical sensitivity: a 1% move in Brent Crude Oil coincided with a -0.26% co-movement (correlation: -0.15). Descriptive historical relationship, not predictive. |
| US 10Y Treasury Yield | -0.44 | -0.11 | Trailing 1Y historical sensitivity: a 1% move in US 10Y Treasury Yield coincided with a -0.44% co-movement (correlation: -0.11). Descriptive historical relationship, not predictive. |
How to read Beta & Correlation ( Beta > 1 = wider swings than market; < 1 = calmer )▾
Sensitivities measure historical 1-year regression beta and correlation across paired daily trading sessions over the past 252 trading days. Past relationships can shift over time and do not guarantee future co-movement.
Trailing Returns Breakdown
Calendar-aligned historical percentage performance across standard market windows.
| Period | Start Price | Current Price | Return (%) |
|---|---|---|---|
| 1 Week | ₹14.93 | ₹14.37 | -3.75% |
| 15 Days | ₹17.13 | ₹14.37 | -16.11% |
| 1 Month | ₹16.83 | ₹14.37 | -14.62% |
| 3 Months | ₹19.10 | ₹14.37 | -24.76% |
| 6 Months | ₹19.10 | ₹14.37 | -24.76% |
| 1 Year | ₹19.10 | ₹14.37 | -24.76% |
| 3 Years | ₹19.10 | ₹14.37 | -24.76% |
| 5 Years | ₹19.10 | ₹14.37 | -24.76% |
Price Swings & Biggest Historical Drops
How much this stock typically fluctuates and its largest peak-to-bottom drops over 1 and 5 years.
Calendar-Year Historical Performance
Annual performance breakdown comparing first and last closing sessions of each calendar year.
| Calendar Year | Start Close | End Close | Annual Return | Trajectory Bar |
|---|---|---|---|---|
| CY 2026 | ₹19.10 | ₹14.37 | -24.8% |
Historical Investment Simulator
Factual simulation of past returns in VIVO BIO TECH (VIVOBIOT) using real recorded closing prices.
Corporate Actions History
No dividend or stock split distributions recorded in historical feeds for VIVOBIOT.
Recent News & Official Exchange Announcements
Official exchange filings, order wins, and company updates. Click any announcement to see how it affects the business on the right.
Vivo Bio Tech: తెలంగాణ ల్యాబ్లో భారీ అగ్నిప్రమాదం.. కీలక శాంపిల్స్ ధ్వంసం! - Whalesbook
Vivo Bio Tech: తెలంగాణ ల్యాబ్లో భారీ అగ్నిప్రమాదం.. కీలక శాంపిల్స్ ధ్వంసం! Whalesbook
Vivo Bio Tech: ਵਿਸਤਾਰ ਦੇ ਚੱਕਰ 'ਚ ਕੰਪਨੀ ਨੂੰ ਹੋਇਆ **₹1.71 ਕਰੋੜ** ਦਾ ਨੁਕਸਾਨ - Whalesbook
Vivo Bio Tech: ਵਿਸਤਾਰ ਦੇ ਚੱਕਰ 'ਚ ਕੰਪਨੀ ਨੂੰ ਹੋਇਆ **₹1.71 ਕਰੋੜ** ਦਾ ਨੁਕਸਾਨ Whalesbook
Vivo Bio Tech dispatches FY26 annual report web-link ahead of Sept 30 AGM - scanx.trade
Vivo Bio Tech dispatches FY26 annual report web-link ahead of Sept 30 AGM scanx.trade
Vivo Bio Tech reports FY26 net loss, publishes results - scanx.trade
Vivo Bio Tech reports FY26 net loss, publishes results scanx.trade
Q1 results: TCS, Indian Bank, HCL Tech among 13 companies with consistent revenue growth - Upstox
Q1 results: TCS, Indian Bank, HCL Tech among 13 companies with consistent revenue growth Upstox
Why This Matters for the Business
Plain-English breakdown of how the selected announcement connects to revenue, costs, and business drivers.
Ministry of Defence capital acquisitions under Positive Indigenisation lists grant high-margin, sovereign counterparty contracts with multi-year revenue locking.
- •Atmanirbhar Bharat defence procurement mandate sanctions domestic equipment contracts
Volume throughput absorbs fixed manufacturing plant overheads, supporting operating EBITDA margins and cash generation across diversified indian equities units.
Continuous commercial tenders and capital expenditures lock in forward order book-to-bill expansion.
At-a-Glance Health & Momentum Check
While recent announcements reflect past operations, profit margins and return on capital have been tightening as the business absorbs higher costs or new expansion spending.
Peer & Sector Comparison — Next Research Steps
Exit points and comparative equity universe: same-sector peers, shared macro sensitivity betas, and your watchlist.
Common Questions About VIVO BIO TECH (VIVOBIOT)
Key facts on VIVOBIOT share price, historical returns, valuation ratios, and past SIP performance.
What is the current share price and 52-week range of VIVO BIO TECH (VIVOBIOT)?
As of 16 Oct 2026, the official closing share price of VIVO BIO TECH (VIVOBIOT) on NSE/BSE is ₹14.37 (+3.16% vs the previous close). Over the past 52 weeks, VIVOBIOT has traded between a low of ₹13.87 and a high of ₹19.29, with a reported market capitalization of ₹33.13 Cr.
What are the historical returns of VIVO BIO TECH (VIVOBIOT)?
Based on split-adjusted closing prices through 16 Oct 2026, VIVO BIO TECH (VIVOBIOT) recorded the following trailing price returns: 1 Week: -3.75% (from ₹14.93 to ₹14.37); 15 Days: -16.11% (from ₹17.13 to ₹14.37); 1 Month: -14.62% (from ₹16.83 to ₹14.37); 3 Months: -24.76% (from ₹19.10 to ₹14.37); 6 Months: -24.76% (from ₹19.10 to ₹14.37); 1 Year: -24.76% (from ₹19.10 to ₹14.37); 3 Years: -24.76% (from ₹19.10 to ₹14.37); 5 Years: -24.76% (from ₹19.10 to ₹14.37). Past performance reflects historical exchange records and does not predict future returns.
What is the P/E ratio, P/B ratio, and dividend yield of VIVO BIO TECH (VIVOBIOT)?
VIVO BIO TECH (VIVOBIOT) currently trades at a trailing Price-to-Earnings (P/E) ratio of not applicable (or negative trailing earnings), a Price-to-Book (P/B) ratio of 0.3x, and a trailing 12-month dividend yield of 0.00%. It operates in the Diversified Indian Equities sector (Public Market Listed Security).
How much would a past lump-sum or monthly SIP investment in VIVOBIOT have grown?
Based on historical closing prices for VIVO BIO TECH (VIVOBIOT): A one-time lump-sum investment of ₹1,00,000.00 held for 5 years would be worth ₹75,235.60 (-24.8% total return, -82.8% CAGR), while a monthly SIP of ₹10,000.00 over 5 years (total invested: ₹30,000.00) would be worth ₹23,764.81 (-20.8% absolute return). You can test custom amounts and holding periods in the interactive calculator above.
Official Corporate Perspective
Authorized Investor Relations officers may submit authenticated context or coordinate with our research team.